Clinical Trial Update: Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluates the efficacy, safety, and pharmacokinetics of a six-month formulation of triptorelin in children with central precocious puberty, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Precocious Puberty

Drugs mentioned

• Triptorelin six-month formulation (triptorelin)

Snippet

Sponsor: Debiopharm International SA | Conditions: Central Precocious Puberty | Phase 3 | Status: COMPLETED | Results posted: 2015-09-04